These results suggest a role of Gal-3 in the regulation of fatty acid and collagen accumulation, thereby indicating that approaches aimed at inhibiting Gal-3 may represent a promising therapeutic strategy in MASLD. Here, LGALS3 is linked to metabolic dysfunction-associated steatotic liver disease.